Key result
Third-generation beta-blockers, such as nebivolol, vasodilate via endothelium-derived nitric oxide synthesis, offering different benefits and lower metabolic risks than traditional beta-blockers.
Answers are grounded in this paper and cite their sources.
Third-generation beta-blockers provide unique vasodilatory benefits through nitric oxide synthesis and have a more favorable metabolic profile than traditional beta-blockers.
BACKGROUND: The sympathetic nervous system has a unique role in endothelial function, and beta-receptors are a key part of sympathetic nervous system function. OBJECTIVE: To elucidate the pharmacological augmentation of endotheliumderived nitric oxide synthesis. SUMMARY: Beta-blockers have been commercially available since the 1960s. Stimulating beta-receptors causes dilatation whereas blocking betareceptors, as traditional beta-blockers do, cause vasoconstriction. However, beta-blockers are hypotensives. This effect probably occurs because they inhibit renin in the kidney and juxtaglomerular apparatus, especially at high doses. They also have some central effects because of central inhibition of the sympathetic nervous system that also lowers blood pressure. In addition, evidence suggests that beta-blockers work at the vascular biology level to produce nitric oxide release. Beta-blockers differ in terms of their betareceptor selectivity, intrinsic sympathomimetic activity, and benefit/risk in diabetes and insulin sensitivity. Nebivolol, the newest of the beta-blockers, is long acting and the most cardioselective beta1-blocker currently available. Nebivolol-induced endothelium- dependent vasodilation associated with activation of the L-arginine/ nitric oxide pathway may confer benefits to patients. The risk for diabetes is lower, the metabolic effects are lower, and people with diabetes who have clear nitric oxide dysfunction may have particular benefits from this agent. CONCLUSION: Third-generation beta-blockers, such as labetolol, carvedilol, bucindolol, and nebivolol, vasodilate by different mechanisms, behaving differently than traditional beta blockers and offering different benefits.
No takes yet. Share an insight, caveat, or question.
George L. Bakris (2007) reported a review. Third-generation beta-blockers vs. Traditional beta-blockers was evaluated. Third-generation beta-blockers, such as nebivolol, vasodilate via endothelium-derived nitric oxide synthesis, offering different benefits and lower metabolic risks than traditional beta-blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: